Last reviewed · How we verify

NCT04136743: MFAT-SCI

Ultrasound-Guided Treatments for Shoulder Pain in Wheelchair Users With Spinal Cord Injury

Status unknown Phase 2 Last updated 14 October 2022
What this trial tests

Phase 2 trial testing Lipogems in Spinal Cord Injuries in 24 participants. Status unknown.

Timeline
14 June 2019
Primary endpoint
30 April 2023
30 April 2024

Quick facts

Lead sponsorKessler Foundation
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment24
Start date14 June 2019
Primary completion30 April 2023
Estimated completion30 April 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Kessler Foundation

Who can join

Adults 18 to 70, any sex, with Spinal Cord Injuries or Tendinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rotator cuff disease (i.e., rotator cuff tendinopathy or tear) is a common cause of shoulder pain in persons with chronic spinal cord injury (SCI). It usually resolves with non-operative treatments such as pharmacological agents and physical therapy; however, when this fails, rotator cuff surgery may be the only option. Corticosteroid injections are another alternative to provide temporary relief, but can over time accelerate degeneration of the tendon and lead to further damage. Autologous adipose tissue injection has recently emerged as a promising new treatment for joint pain and soft tissue injury. Adipose can be used to provide cushioning and filling of structural defects and has been shown to have an abundance of bioactive elements and regenerative perivascular cells (pericytes). The purpose of this study is to explore the efficacy of autologous, micro-fragmented adipose tissue (Lipogems®) injection under ultrasound guidance for chronic shoulder pain in persons with SCI compared with the standard-of-care, corticosteroid injection.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Wharton's jelly mesenchymal stem cells: Future regenerative medicine for clinical applications in mitigation of radiation injury.
    Sharma P, Maurya DK. · · 2024 · cited 12× · PMID 39086560 · DOI 10.4252/wjsc.v16.i7.742
  2. Pericytes and Diabetic Microangiopathies: Tissue Resident Mesenchymal Stem Cells with High Plasticity and Regenerative Capacity.
    Shirbaghaee Z, Sorenson CM, Sheibani N. · · 2025 · cited 1× · PMID 40508141 · DOI 10.3390/ijms26115333

Verify or expand the search:

Other trials of Lipogems

Trials testing the same drug.

Other recruiting trials for Spinal Cord Injuries

Currently open trials in the same condition.

Other Kessler Foundation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04136743.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing